Market Research Logo

Generics in Russia


Attention: There is an updated edition available for this report.

Generics in Russia

Summary

Generics in Russia industry profile provides top-line qualitative and quantitative summary information including: market size (value and volume 2012-16, and forecast to 2021). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market.

Essential resource for top-line data and analysis covering the Russia generics market. Includes market size data, textual and graphical analysis of market growth trends, leading companies and macroeconomic information.

For the purposes of this profile, a generic is defined as a copy of an ethical (prescription) drug formerly protected by patents that have now expired. Both unbranded generics and all branded generics are included. However, off-patent drugs that continue to be offered by the original manufacturer under the original name, and which form part of the 'generic-eligible' market, are not included.

The Russian generics market is expected to generate total revenues of $7.0bn in 2016, representing a compound annual growth rate (CAGR) of 14% between 2012 and 2016.

Market consumption volume is forecast to decline with a compound annual rate of change (CARC) of -1.1% between 2012 and 2016, to reach a total of 79% of total pharma volume in 2016.

The Russian pharmaceuticals market is large and dominated by “branded” generic products and imports. The system is largely undeveloped, as the majority of drugs are bought by patients themselves, who are greatly influenced by advertising. The country has around 500 pharmaceutical companies but many are small. The companies’ size and the investment in marketing and sales rather than creation means that mainly older drugs are produced.

Scope

  • Save time carrying out entry-level research by identifying the size, growth, and leading players in the generics market in Russia
  • Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the generics market in Russia
  • Leading company profiles reveal details of key generics market players’ global operations and financial performance
  • Add weight to presentations and pitches by understanding the future growth prospects of the Russia generics market with five year forecasts by both value and volume
Reasons to buy
  • What was the size of the Russia generics market by value in 2016?
  • What will be the size of the Russia generics market in 2021?
  • What factors are affecting the strength of competition in the Russia generics market?
  • How has the market performed over the last five years?
  • How large is Russia’s generics market in relation to its regional counterparts?


Executive Summary
Market value
Market value forecast
Market volume
Market volume forecast
Geography segmentation
Market rivalry
Market Overview
Market definition
Market analysis
Market Data
Market value
Market volume
Market Segmentation
Geography segmentation
Market Outlook
Market value forecast
Market volume forecast
Five Forces Analysis
Summary
Buyer power
Supplier power
New entrants
Threat of substitutes
Degree of rivalry
Leading Companies
Abbott Laboratories
Krka, d. d., Novo mesto
Teva Pharmaceutical Industries Limited
Macroeconomic Indicators
Country data
Methodology
Industry associations
Related MarketLine research
Appendix
About MarketLine
List of Tables
Table 1: Russia generics market value: $ billion, 2012–16(e)
Table 2: Russia generics market volume: % of total pharma volume, 2012–16(e)
Table 3: Russia generics market geography segmentation: $ billion, 2016(e)
Table 4: Russia generics market value forecast: $ billion, 2016–21
Table 5: Russia generics market volume forecast: % of total pharma volume, 2016–21
Table 6: Abbott Laboratories: key facts
Table 7: Abbott Laboratories: key financials ($)
Table 8: Abbott Laboratories: key financial ratios
Table 9: Krka, d. d., Novo mesto: key facts
Table 10: Krka, d. d., Novo mesto: key financials ($)
Table 11: Krka, d. d., Novo mesto: key financials (€)
Table 12: Krka, d. d., Novo mesto: key financial ratios
Table 13: Teva Pharmaceutical Industries Limited: key facts
Table 14: Teva Pharmaceutical Industries Limited: key financials ($)
Table 15: Teva Pharmaceutical Industries Limited: key financial ratios
Table 16: Russia size of population (million), 2012–16
Table 17: Russia gdp (constant 2005 prices, $ billion), 2012–16
Table 18: Russia gdp (current prices, $ billion), 2012–16
Table 19: Russia inflation, 2012–16
Table 20: Russia consumer price index (absolute), 2012–16
Table 21: Russia exchange rate, 2012–16
List Of Figures
Figure 1: Russia generics market value: $ billion, 2012–16(e)
Figure 2: Russia generics market volume: % of total pharma volume, 2012–16(e)
Figure 3: Russia generics market geography segmentation: % share, by value, 2016(e)
Figure 4: Russia generics market value forecast: $ billion, 2016–21
Figure 5: Russia generics market volume forecast: % of total pharma volume, 2016–21
Figure 6: Forces driving competition in the generics market in Russia, 2016
Figure 7: Drivers of buyer power in the generics market in Russia, 2016
Figure 8: Drivers of supplier power in the generics market in Russia, 2016
Figure 9: Factors influencing the likelihood of new entrants in the generics market in Russia, 2016
Figure 10: Factors influencing the threat of substitutes in the generics market in Russia, 2016
Figure 11: Drivers of degree of rivalry in the generics market in Russia, 2016
Figure 12: Abbott Laboratories: revenues & profitability
Figure 13: Abbott Laboratories: assets & liabilities
Figure 14: Krka, d. d., Novo mesto: revenues & profitability
Figure 15: Krka, d. d., Novo mesto: assets & liabilities
Figure 16: Teva Pharmaceutical Industries Limited: revenues & profitability
Figure 17: Teva Pharmaceutical Industries Limited: assets & liabilities

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report